ADEPT-2 Study is testing a drug named KarXT for people with Alzheimer’s Disease (AD) who have psychosis, which means they may see or hear things that aren't there (hallucinations) or believe things that aren't true (delusions). Alzheimer’s Disease is a brain disorder that slowly destroys memory and thinking skills. This study will compare KarXT to a placebo, which is a pill with no medicine, to see if it helps with psychosis. People who join must be between 55 and 90 years old, have moderate to severe AD, and experience psychosis. They need a study partner who can help them daily. The study is double-blind, meaning neither the doctors nor the participants know who gets the real medicine or the placebo, making the results fairer. Participants need to live in the same place for at least 6 weeks before starting the study.

• Study length: Participation involves multiple visits over time.
• Eligibility: Must meet specific health requirements; certain conditions might exclude participation.
• Safety: The study aims to ensure the safety and effectiveness of KarXT.